 | |
Native name | 長江生命科技集團有限公司 |
|---|---|
| Company type | Public |
| SEHK: 775 | |
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | |
Area served | Hong Kong |
Key people | Victor Li Tzar-kuoi |
| Products | Lifce Sciences products |
| Services | Life Sciences |
| Parent | Cheung Kong Holdings |
| Website | www |
CK Life Sciences International (Holdings) Inc. (Chinese:長江生命科技集團有限公司), orCK Life Sciences, is asubsidiary ofCK Hutchison Holdings. It is engaged inresearch and development, commercialization, marketing and sale ofbiotechnology products.[1] The chairman isVictor Li Tzar-kuoi, the eldest son ofLi Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on theHong Kong Stock Exchange viaGrowth Enterprise Market in 2002 (Former stock code:SEHK: 8222). It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company (Cheetham Salt) as part of its expansion into the agricultural sector.[2]
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024.[3]
| Subsidiaries |  | |
|---|---|---|
| Joint venture | ||
| Equity investments | ||
| Brands | ||
| Company history | ||
| Affiliated company | ||
| Key people | ||